Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
published in: Blood
date of publication: 2009-01-13
language: English
main subject: leukemia, lymphoblastic leukemia
Cites articles
There is nothing here
Article - wd:Q38384261